At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 122 enrolled
Drug / intervention
autologous hematopoietic stem cell transplantation +1 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blind Phase III Clinical Trial Comparing Outcomes of Immunologic Autograft Engineering Versus Standard Autograft Collection in Patients Undergoing Autologous Stem Cell Transplantation for Lymphoma
In Brief
A Phase 3 clinical trial evaluating autologous hematopoietic stem cell transplantation and leukapheresis for Lymphoma. Completed, enrolled 122 participants across 1 site.
Detailed Summary
RATIONALE: It is not yet known which method of stem cell collection is best for patients undergoing an autologous stem cell transplant. PURPOSE: This randomized phase III trial is comparing two different methods of collecting stem cells in patients undergoing stem cell transplant for diffuse large cell lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedDec 2007
Primary CompletionJan 2015
TodayJul 2026
First PostedDec 3, 2007
Enrollment StartDec 1, 2007
Primary CompletionJan 15, 2015
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 18.6 years ago
Interventions
autologous hematopoietic stem cell transplantationprocedure
Patients undergo autologous stem cell transplantation
leukapheresisprocedure
Stem cells collected